Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
QDEL

Quidel Corp

QDEL

66.02USD-0.65 (-0.97%)Market Closed
Watchlist

Market Summary

USD66.02-0.65
Market Closed
-0.97%

QDEL Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

QDEL Stock Price

View Fullscreen

QDEL RSI Chart

QDEL Alerts

QDEL Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

334.1

Price/Sales (Trailing)

1.41

EV/EBITDA

12.46

Price/Free Cashflow

30.04

QDEL Price/Sales (Trailing)

QDEL Profitability

EBT Margin

0.68%

Return on Equity

0.27%

Return on Assets

0.15%

Free Cashflow Yield

3.33%

QDEL Fundamentals

QDEL Revenue

Revenue (TTM)

3.1B

Revenue Y/Y

-5.08%

Revenue Q/Q

11.86%

QDEL Earnings

Earnings (TTM)

13.2M

Earnings Y/Y

-166.15%

Earnings Q/Q

76.13%

Price Action

Last 7 days

-4.6%

Last 30 days

9.5%

Last 90 days

-11.5%

Trailing 12 Months

-31.0%

How does QDEL drawdown profile look like?

QDEL Financial Health

Current Ratio

1.59

QDEL Investor Care

Shares Dilution (1Y)

1.21%

Diluted EPS (TTM)

-1.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.1B3.2B3.1B0
20222.3B2.8B3.0B3.3B
20211.7B1.7B1.7B1.7B
20200001.7B
Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for QDEL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
hodges michelle a.
acquired
-
-
238
svp, general counsel
Dec 01, 2023
hodges michelle a.
sold (taxes)
-8,237
69.22
-119
svp, general counsel
Nov 08, 2023
hodges michelle a.
sold (taxes)
-87,360
60.29
-1,449
svp, general counsel
Nov 08, 2023
hodges michelle a.
acquired
-
-
3,970
svp, general counsel
Oct 15, 2023
bujarski robert joseph
acquired
-
-
390
evp & coo
Oct 15, 2023
hodges michelle a.
acquired
-
-
390
svp, general counsel
Oct 15, 2023
bujarski robert joseph
sold (taxes)
-13,195
68.02
-194
evp & coo
Oct 15, 2023
hodges michelle a.
sold (taxes)
-9,182
68.02
-135
svp, general counsel
Sep 14, 2023
bujarski robert joseph
sold (taxes)
-11,913
76.37
-156
evp & coo
Sep 14, 2023
bujarski robert joseph
acquired
-
-
314
evp & coo

1–10 of 50

Which funds bought or sold QDEL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
24.98
39,166
424,217
 -%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-85.47
-2,090,340
307,133
 -%
Nov 22, 2023
Polar Capital Holdings Plc
reduced
-20.64
-258,262
601,411
 -%
Nov 22, 2023
Aurora Investment Counsel
added
0.53
-96,975
754,577
 0.50%
Nov 21, 2023
TOMPKINS FINANCIAL CORP
unchanged
-
-982
7,304
 -%
Nov 21, 2023
Spears Abacus Advisors LLC
reduced
-84.32
-2,571,580
412,457
 0.04%
Nov 21, 2023
COMERICA BANK
new
-
5,156,400
5,156,400
 0.03%
Nov 17, 2023
Seelaus Asset Management LLC
sold off
-100
-911,000
-
 -%
Nov 15, 2023
HARBOUR INVESTMENTS, INC.
sold off
-100
-83.00
-
 -%
Nov 15, 2023
Virtu Financial LLC
sold off
-100
-331,000
-
 -%

1–10 of 40

Latest Funds Activity

Are funds buying QDEL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own QDEL
No. of Funds

Schedule 13G FIlings of Quidel Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 05, 2022
senvest management, llc
5.17%
2,161,521
SC 13G
Feb 14, 2022
alger associates inc
5.3%
2,223,343
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
14.6%
6,108,899
SC 13G/A
Feb 14, 2022
brown capital management llc
6.34%
2,642,671
SC 13G/A
Feb 10, 2022
vanguard group inc
8.22%
3,426,080
SC 13G/A
Feb 01, 2022
blackrock inc.
7.9%
3,301,994
SC 13G/A
Apr 12, 2021
price t rowe associates inc /md/
15.1%
6,425,323
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
10.1%
4,261,838
SC 13G/A
Feb 16, 2021
feinberg larry n
4.47%
1,879,121
SC 13G/A
Feb 12, 2021
brown capital management llc
5.43%
2,282,444
SC 13G/A

Recent SEC filings of Quidel Corp

View All Filings
Date Filed Form Type Document
Dec 08, 2023
3
Insider Trading
Dec 05, 2023
4
Insider Trading
Dec 01, 2023
8-K
Current Report
Nov 13, 2023
4
Insider Trading
Nov 02, 2023
10-Q
Quarterly Report
Nov 01, 2023
8-K
Current Report
Oct 17, 2023
4
Insider Trading
Oct 17, 2023
4
Insider Trading
Oct 12, 2023
8-K
Current Report
Sep 18, 2023
4
Insider Trading

Quidel Corp News

Latest updates
Insider Monkey • 02 Nov 2023 • 07:00 am • 37 days ago
QuidelOrtho Corporation (NASDAQ:QDEL) Q3 2023 Earnings Call ...
Reuters • 29 Sep 2023 • 07:00 am • 2 months ago
Exclusive: Carlyle in exclusive talks for $7 billion-plus Medtronic ...
Bloomberg • 23 Dec 2021 • 08:00 am • 23 months ago
Quidel to Acquire Ortho Clinical Diagnostics for $6 Billion
Zonebourse.com • 23 Dec 2021 • 08:00 am • 23 months ago
Quidel rachète Ortho Clinical Diagnostics pour 6 milliards de dollars
ThinkMarkets • 15 Jun 2021 • 04:37 pm • 2 years ago
Our Contract Specifications - Get Trading
Mass Device • 04 Feb 2021 • 08:00 am • 2 years ago
Quidel opens new COVID-19 antigen test factory in Calif.
Yahoo Finance • 14 Jan 2021 • 08:00 am • 2 years ago
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
Investing.com • 11 Jan 2021 • 08:00 am • 2 years ago
T. Rowe Price Equity Income Fund increased stake in Proofpoint Inc ...
Mass Device • 24 Dec 2020 • 08:00 am • 2 years ago
Quidel wins EUA for COVID-19 test with faster runtime
Investor's Business Daily • 03 Dec 2020 • 08:00 am • 3 years ago
Fastest-Growing Companies: See 27 Stocks Expecting Up To 711 ...
Reuters • 03 Nov 2020 • 08:00 am • 3 years ago
U.S. FDA warns about false positive results from COVID-19 antigen ...
The Wall Street Journal • 15 Sep 2020 • 07:00 am • 3 years ago
Covid-19 Test Maker Examines False-Positive Results in Nursing ...
Yahoo Finance • 14 Sep 2020 • 07:00 am • 3 years ago
Hedge Funds Have Never Been This Bullish On Quidel Corporation ...
AsiaOne • 28 May 2020 • 07:00 am • 3 years ago
Best US Exchange Traded Funds (ETFs) in 2020, Money News
Investing.com Россия • 07 Feb 2017 • 10:59 pm • 6 years ago
Акции Quidel (QDEL) — Investing.com

Financials for Quidel Corp

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue11.9%7446658468677846131,002637510177--
Gross Profit-------740489373106302701
Costs and Expenses-------11911392.0083.0078.0084.00
  S&GA Expenses8.4%19417920221420411885.0074.0063.0054.00--
  R&D Expenses-0.6%62.0063.0062.0064.0066.0034.0026.0026.0024.0023.00--
EBITDA Margin-8.8%0.11*0.12*----0.57*0.54*0.62*0.64*0.66*0.64*
Interest Expenses100.0%--36.50-36.70-34.70-29.70-10.30-1.00-1.10-1.30-1.40--
Income Taxes75.0%-2.80-11.2011.0011.0012.0024.0014184.0066.003.00--
Earnings Before Taxes75.9%-15.50-64.4060.0041.0031.0043.0062137528222.00--
EBT Margin-68.4%0.01*0.02*----0.56*0.53*0.61*0.63*0.65*0.63*
Net Income76.1%-12.70-53.2049.0030.0019.0019.0048029121619.00178-
Net Income Margin-70.4%0.00*0.01*----0.43*0.41*0.47*0.49*0.51*0.49*
Free Cashflow97.7%-1.90-81.90----479289-29.80-253507410
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets-0.1%8,5398,5508,7878,8568,6568,8225,6262,430
  Current Assets4.8%1,3711,3081,4991,5751,4451,559-1,440
    Cash Equivalents-16.1%1501793542932123811,276803
  Inventory1.8%552542529524536553-199
  Net PPE-0.5%1,3691,3761,3621,3391,2621,110-349
  Goodwill-1.1%2,4432,4712,4912,4772,3582,590-337
Liabilities0.7%3,5723,5483,7913,9213,8603,9032,202501
  Current Liabilities8.9%8607909081,007873900-324
Shareholder's Equity-0.7%4,9675,0034,9974,9354,7954,9202,4151,929
  Retained Earnings-0.6%2,1812,1942,2472,1982,1682,148-1,649
  Additional Paid-In Capital0.5%2,8392,8252,8092,8042,7722,832-280
Shares Outstanding0%67.0067.0067.0066.0066.0052.0042.0042.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations235.6%41,500,000-30,600,000188,900,000169,400,000-9,700,000224,700,000500,900,000321,400,00077,000,000---
  Share Based Compensation-0.7%14,100,00014,200,00011,000,00011,800,00013,300,00015,900,0007,400,0006,700,0007,000,000---
Cashflow From Investing49.6%-21,300,000-42,300,000-68,900,000-59,300,000-29,800,000-1,530,400,000-24,700,000-96,000,000-93,200,000---
Cashflow From Financing51.2%-48,700,000-99,700,000-59,600,000-31,700,000-126,000,000413,100,000-3,400,000-900,0001,800,000---
  Buy Backs-----74,300,000----103,400,000--

QDEL Income Statement

2023-10-01
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Oct. 01, 2023
Oct. 02, 2022
Oct. 01, 2023
Oct. 02, 2022
Income Statement [Abstract]    
Total revenues$ 744.0$ 783.8$ 2,255.2$ 2,399.5
Cost of sales, excluding amortization of intangibles375.9376.31,142.1912.5
Selling, marketing and administrative194.1204.2575.6407.4
Research and development62.465.6187.5126.2
Amortization of intangible assets51.450.5153.678.6
Acquisition and integration costs26.526.480.4109.6
Other operating expenses7.44.017.08.0
Operating income26.356.899.0757.2
Interest expense, net37.729.7110.941.0
Loss on extinguishment of debt0.00.00.024.0
Other expense (income), net4.1(4.2)8.0(2.6)
(Loss) income before income taxes(15.5)31.3(19.9)694.8
(Benefit from) provision for income taxes(2.8)12.1(2.8)176.4
Net (loss) income$ (12.7)$ 19.2$ (17.1)$ 518.4
Basic (loss) earnings per share$ (0.19)$ 0.29$ (0.26)$ 9.67
Diluted (loss) earnings per share$ (0.19)$ 0.28$ (0.26)$ 9.56
Weighted-average shares outstanding - basic66.966.966.853.6
Weighted-average shares outstanding - diluted66.967.566.854.2

QDEL Balance Sheet

2023-10-01
Consolidated Balance Sheets - USD ($)
$ in Millions
Oct. 01, 2023
Jan. 01, 2023
Current assets:  
Cash and cash equivalents$ 149.3$ 292.9
Marketable securities43.952.1
Accounts receivable, net331.2453.9
Inventories551.7524.1
Prepaid expenses and other current assets295.2252.1
Total current assets1,371.31,575.1
Property, plant and equipment, net1,369.41,339.0
Marketable securities11.921.0
Right-of-use assets172.2181.0
Goodwill2,442.92,476.8
Intangible assets, net2,976.53,123.8
Deferred tax asset15.716.4
Other assets179.2122.7
Total assets8,539.18,855.8
Current liabilities:  
Accounts payable253.0283.3
Accrued payroll and related expenses106.8139.2
Income tax payable1.851.6
Current portion of borrowings193.0207.5
Other current liabilities305.4325.4
Total current liabilities860.01,007.0
Operating lease liabilities175.9186.4
Long-term borrowings2,274.62,430.8
Deferred tax liability196.5213.2
Other liabilities65.483.8
Total liabilities3,572.43,921.2
Commitments and contingencies (Note 10)
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 5.0 shares authorized; none issued or outstanding at October 1, 2023 and January 1, 20230.00.0
Common stock, $0.001 par value per share; 126.2 shares authorized; 66.8 and 66.4 shares issued and outstanding at October 1, 2023 and January 1, 2023, respectively0.10.0
Additional paid-in capital2,839.02,804.3
Accumulated other comprehensive loss(53.2)(67.6)
Retained earnings2,180.82,197.9
Total stockholders’ equity4,966.74,934.6
Total liabilities and stockholders’ equity$ 8,539.1$ 8,855.8

About Quidel Corp

QDEL
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
 CEO
 WEBSITEwww.quidelortho.com
 EMPLOYEES7000

Quidel Corp Frequently Asked Questions

What is the ticker symbol for Quidel Corp? What does QDEL stand for in stocks?

QDEL is the stock ticker symbol of Quidel Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quidel Corp (QDEL)?

As of Fri Dec 08 2023, market cap of Quidel Corp is 4.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QDEL stock?

You can check QDEL's fair value in chart. The fair value of Quidel Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quidel Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QDEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quidel Corp a good stock to buy?

The fair value guage provides a quick view whether QDEL is over valued or under valued. Whether Quidel Corp is cheap or expensive depends on the assumptions which impact Quidel Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QDEL.

What is Quidel Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, QDEL's PE ratio (Price to Earnings) is 334.1 and Price to Sales (PS) ratio is 1.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QDEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Quidel Corp's stock?

In the past 10 years, Quidel Corp has provided 0.106 (multiply by 100 for percentage) rate of return.